Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
$5.17
$0.48(33.57%)
At close: 4:00 PM EST
$5.17
$0.48(33.57%)
Day’s Range― - ―
52-Week Range$1.60 - $6.88
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.19M
Market Cap
$931.05M
Enterprise Value$694.13M
Total Cash (Recent Filing)$208.91M
Total Debt (Recent Filing)$9.83M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
May 13, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding180,087,920
10 Day Avg. Volume2,116,070
30 Day Avg. Volume2,186,009
Financial Highlights & Ratios
PEG Ratio-0.76
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.21
Forecast
1Y Price Target
$13.50Price Target Upside161.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$1.42M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutTop-line progression-free survival and crossover-adjusted overall survival data from the pivotal COMPANION-002 study could demonstrate a meaningful treatment benefit and support regulatory approval and physician adoption.
Pipeline Expansion And Financial RunwayPositive cohort data for the company's bispecific immunotherapy in breast and lung cancers, combined with a multi-year cash runway, could broaden the market opportunity and lift investor expectations.
Regulatory And Pricing DynamicsOrphan drug designation and a first-in-class profile may enable stronger pricing power and a more favorable regulatory review, enhancing the therapy's commercial value.
Bears Say
Comparator Choice And GeneralizabilityUse of paclitaxel as the comparator and exclusion of patients with biliary drains could limit how regulators and clinicians view the trial's applicability to typical patients.
Efficacy Consistency And Binary Outcome RiskA decline in observed response rates versus earlier data and reliance on a single pivotal readout create uncertainty that could trigger significant share-price volatility if results disappoint.
Overall Survival InterpretationHigh patient crossover from the control arm may confound unadjusted overall survival analyses and make it harder to demonstrate a clear survival benefit.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.60 and its highest was $6.88 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $931.05M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 32 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Mar 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.004.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 180,087,920 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went down -2.812%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compass Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (161.12% Upside)
$13.50 (161.12% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 244.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
211.42%
12-Months-Change
Fundamentals
Return on Equity
-43.61%
Trailing 12-Months
Asset Growth
58.22%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Stock 12 Month Forecast
Average Price Target
$13.50
▲(161.12% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
Currently, No data available
---